Meeting
2022 ASCO Annual Meeting
Acalabrutinib in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL): Results of a phase 2, multicenter, open-label trial.
Authors
L Elizabeth Budde
City of Hope National Medical Center, Duarte, CA
L Elizabeth Budde , Morton Coleman , Don A. Stevens , Shuo Ma , Caterina Patti , M. Yair Levy , Izidore S. Lossos , Praveen Ramakrishnan Geethakumari , Selay Lam , Roser Calvo , Kara Higgins , Paolo Strati
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies
Sub Track
Non-Hodgkin Lymphoma
Clinical Trial Registration Number
NCT02180711
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 7549)
DOI
10.1200/JCO.2022.40.16_suppl.7549
Abstract #
7549
Poster Bd #
202
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Dabrafenib + trametinib (dab + tram) in relapsed/refractory (r/r) BRAF V600–mutant pediatric high-grade glioma (pHGG): Primary analysis of a phase II trial.
First Author: Darren R. Hargrave
Poster
2022 ASCO Annual Meeting
Primary analysis from the phase 2 study of continuous talazoparib (TALA) plus intermittent low-dose temozolomide (TMZ) in patients with relapsed or refractory extensive-stage small cell lung cancer (ES-SCLC).
First Author: Jonathan W. Goldman
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Pivotal single-arm, phase 2 trial of tasurgratinib for patients with fibroblast growth factor receptor (FGFR)-2 gene fusion-positive cholangiocarcinoma (CCA).
First Author: Junji Furuse
Poster
2023 ASCO Annual Meeting
Two schedules of vincristine, irinotecan and temozolomide (VIT) for patients with relapsed or refractory Ewing sarcoma: A randomized controlled phase 2 trial.
First Author: Jie Xu